This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Digging into the use of Esperion's NEXLETOL (bempedoic acid) in atherosclerotic cardiovascular disease (ASCVD)
Ticker(s): ESPRWho's the expert?
Institution: Providence St. Joseph Heart Institute
- Medical director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence St. Joseph Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins Hospital in Baltimore, Maryland.
- Manages 675 patients with ASCVD & 11 patients with pericarditis.
- Principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies.
Interview GoalThis conversation will focus on atherosclerotic cardiovascular disease (ASCVD) and the use of bempedoic acid (NEXLETOL) ahead of the CVOT outcome studies from Esperion.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
